The hepatoprotective and hypolipidemic effects of Spirulina () supplementation in a Cretan population with non-alcoholic fatty liver disease: a prospective pilot study.

Background: A pilot study was conducted to determine the effects of Spirulina () on Cretan patients with non-alcoholic fatty liver disease (NAFLD). Spirulina is a filamentous cyanobacterium taken as a dietary supplement.

Methods: Fifteen adult Cretan outpatients (13 men), median age 48 (range: 29-62) years, with NAFLD were orally supplemented with 6 g of Spirulina (Greek production) per day for six months.